TICKERNERD
Menu
BDXBDXHealthcare · Medical Instruments & Supplies

BDX Stock Forecast: Becton, Dickinson & Co. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$181
+2.19% on the day

The 14 Wall Street analysts covering Becton, Dickinson & Co. hold a median 12-month price target of $198 — +9.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 3 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$48.2B
Ticker Nerd rank
93 / 100
Median analyst target
$198
Analysts covering
14
Revenue$5.0B−9.5% y/y
Operating income$752.0M
Net income$377.0M
Free cash flow$508.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.7%
1M
−1.6%
YTD
+20.7%
1Y
+21.8%
From 52W high
−5.3%
From 52W low
+33.7%
$135
$191
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Becton, Dickinson & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
98
Volatility
97
Value
93
Revisions
79
Accruals
78
Momentum
76
Quality
69
Growth
41
Size
5

Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (41): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$140$160$180$200$220$240Jan 26Apr 26Jul 26Oct 26BDXHigh $225Median $198Low $170

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
7 Buy7 Hold0 Sell
Low $170Median $198High $225

The green dot is the last close — the median target sits +9.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
31 Aug 2026B of A SecuritiesMaintainsNeutral$185 → $200
13 Aug 2026RBC CapitalMaintainsSector Perform$180 → $190
13 Aug 2026RBC CapitalMaintainsSector Perform—
7 Aug 2026CitigroupMaintainsBuy$198 → $204
7 Aug 2026CitigroupMaintainsBuy—
7 Aug 2026Piper SandlerMaintainsNeutral$161 → $175
7 Aug 2026Piper SandlerMaintainsNeutral—
7 Aug 2026RBC CapitalMaintainsSector Perform$175 → $180
7 Aug 2026RBC CapitalMaintainsSector Perform—
7 Aug 2026Wells FargoMaintainsEqual-Weight$161 → $170
7 Aug 2026Wells FargoMaintainsEqual-Weight—
5 Aug 2026TD CowenMaintainsHold—
5 Aug 2026TD CowenMaintainsHold$163 → $182
28 July 2026UBSInitiatesBuy—
28 July 2026UBSInitiatesBuy$190
6 July 2026Evercore ISI GroupMaintainsOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$190 → $180
11 May 2026BarclaysMaintainsOverweight—
8 May 2026Wells FargoMaintainsEqual-Weight—
4 May 2026TD CowenMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Becton, Dickinson & Co. returned +21.8% against +17.0% for the S&P 500, dividends included.

BDX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26BDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.7%
Analysts raising
11
Analysts cutting
0
Fundamentals

Becton, Dickinson & Co. (BDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
41.1×

Cheaper than 18% of US stocks

Price / sales
2.1×

Cheaper than 50% of US stocks

Price / book
2.0×

Cheaper than 45% of US stocks

EV / EBITDA
10.5×

Cheaper than 36% of US stocks

Growth & margins
Revenue growth (YoY)
5.4%

Higher than 40% of US stocks

Earnings growth (YoY)
−34.3%

Higher than 15% of US stocks

Gross margin
46.5%

Higher than 58% of US stocks

Operating margin
15.7%

Higher than 73% of US stocks

Net margin
4.2%

Higher than 58% of US stocks

Returns & dividend
Return on equity
6.6%

Higher than 56% of US stocks

Return on assets
4.3%

Higher than 73% of US stocks

Dividend yield
2.4%

Higher than 69% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Becton, Dickinson & Co. (BDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Becton, Dickinson & Co. has a market value of $48.2B and an enterprise value of $64.3B.

  • Revenue in the twelve months to 30 June 2026: $20.8B. The latest quarter grew 5.4% year on year.

  • Net income over the same four quarters: $941.0M, a 4.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $2.5B, after $728.0M of capital spending.

  • Becton, Dickinson & Co. spent $1.2B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 272.4M.

  • Trailing P/E: 41.1×; forward P/E: 13.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.38%, paying out 72% of earnings.

  • Becton, Dickinson & Co. employs 72,000 people — $289K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

BDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BDXBecton, Dickinson & Co.$48.2B
93
MDLNMedline, Inc.$46.8B
19
RMDResMed, Inc.$32.0B
72
ALCAlcon AG$31.8B
68
WSTWest Pharmaceutical Services, Inc.$26.3B
94
ISRGIntuitive Surgical, Inc.$140.5B
72
SOLVSolventum Corp.$15.2B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Becton, Dickinson & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BDX news & analysis

5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve

Zacks Investment Research · 1 Oct 2026positive

Zacks Investment Research highlighted five medical supplies stocks to watch amid improving industry prospects, listing BDX among them along with MCK, CAH, MMSI, and PDEX. The report notes these companies show strong potential that investors should keep on their watchlist.

Why it matters — BDX watchers would care because the company is being singled out among a shortlist of medical supplies stocks expected to benefit from improving industry conditions.

3 Historically Stable Dividend Raisers in Medical Devices Offering Solid Yields With Fortress-Like Growth

24/7 Wall Street · 29 Sept 2026positive

24/7 Wall Street highlights three historically stable medical device companies that have raised their dividends consistently for decades, benefiting from steady demand for products like pacemakers and glucose monitors regardless of economic conditions.

Why it matters — A BDX watcher would care because this piece frames medical device makers as fortress-like dividend growth stories, positioning BDX within a group known for reliable, annually increasing payouts.

BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy

PRNewsWire · 29 Sept 2026positive

BD celebrated 70 years of manufacturing in Sandy, Utah, marking a milestone for a key part of its U.S. manufacturing network that supplies essential medical technologies used by clinicians and patients worldwide.

Why it matters — The anniversary highlights the longevity and reliability of a critical U.S. manufacturing site in BD's global supply chain for essential medical devices.

Here's Why You Should Retain BDX Stock in Your Portfolio for Now

Zacks Investment Research · 28 Sept 2026positive

Zacks Investment Research notes that Becton, Dickinson's MedTech transformation, innovation pipeline, and strategic partnerships continue to support growth, despite reimbursement and macroeconomic pressures. The report suggests retaining BDX stock in a portfolio for now.

Why it matters — A BDX watcher would care because this highlights the company's growth drivers and its resilience against reimbursement and macroeconomic headwinds, informing whether to hold the stock.

Arthur Hu to Join BD as Chief Information and Digital Officer

PRNewsWire · 21 Sept 2026neutral

BD announced that Arthur (Art) Hu has been appointed executive vice president and chief information and digital officer, effective September 30. The appointment was announced on September 21, 2026.

Why it matters — BDX watchers may be interested in the company's senior leadership and digital strategy direction under a new chief information and digital officer.

FAQ

Frequently asked questions about BDX stock

What is the BDX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Becton, Dickinson & Co. have a median 12-month price target of $198, with estimates ranging from $170 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BDX stock a buy right now?

Of the 14 analysts covering Becton, Dickinson & Co., 7 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Becton, Dickinson & Co. 93 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BDX?

As at 3 Oct 2026, Becton, Dickinson & Co. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).

Will BDX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +9.3% from the last close, and Ticker Nerd's factor model ranks Becton, Dickinson & Co. 93 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BDX stock forecast for 2030?

No analyst covering Becton, Dickinson & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $170 to $225 over the next 12 months.

How has BDX stock performed over the past year?

Becton, Dickinson & Co. returned +21.8% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Becton, Dickinson & Co. do?

Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad range of products used across healthcare and life sciences. Becton, Dickinson and Company serves hospitals, physicians, clinical laboratories, researchers, and public health organizations with medical supplies, diagnostic systems, laboratory equipment, and interventional devices.

What is the latest news on BDX?

The most recent item we track (Zacks Investment Research, 1 Oct 2026): "5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve". Zacks Investment Research highlighted five medical supplies stocks to watch amid improving industry prospects, listing BDX among them along with MCK, CAH, MMSI, and PDEX. The report notes these companies show strong potential that investors should keep on their watchlist.

Company

About Becton, Dickinson & Co.

Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad range of products used across healthcare and life sciences. Becton, Dickinson and Company serves hospitals, physicians, clinical laboratories, researchers, and public health organizations with medical supplies, diagnostic systems, laboratory equipment, and interventional devices. Its current business centers on medical essentials, connected care, biopharma systems, and interventional products, supporting workflows such as specimen handling, medication delivery, infection prevention, vascular access, and surgical procedures. The company’s portfolio also includes tools and technologies used in drug delivery, patient safety, and clinical research. Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company plays an important role in enabling medical discovery, improving care delivery, and supporting routine operations in healthcare settings worldwide.

CEO Mr. Thomas E. Polen Jr. · 72,000 employees · United States · https://www.bd.com